Search by product name, CAS, target or catalog number. Press Down Arrow to reach product suggestions, Tab to move between links, and Escape to close suggestions.
Low-density lipoprotein (LDL) research compounds span lipid transport, absorption and oxidative modification. LDL particles carry lipids in circulation and interact with cellular uptake pathways, linking their composition and processing to lipid homeostasis. Ezetimibe is associated with intestinal sterol absorption, anacetrapib with cholesteryl ester transfer protein, and probucol with oxidative processes. LDL-IN-4 is listed as an LDL oxidation inhibitor. The category therefore brings together compounds with distinct molecular targets and research roles rather than a single receptor-directed class.
Synonyms: MK0859
Anacetrapib (MK-0859) is a CETP inhibitor being developed to treat hypercholesterolemia (elevated cholesterol levels) and prevent cardiovascular disease.
LDL-IN-4 is a selective inhibitor of human acyl-CoA:cholesterol acyltransferase-1 and -2, effectively targeting the oxidation of low-density lipoprotein (LDL). This compound demonstrates significant inhibitory activity against copper-mediated LDL oxidation, with an IC50 value of 3 μM. LDL-IN-4 exhibits anti-atherosclerotic properties, making it a valuable tool for research focused on cardiovascular health and lipid metabolism.
